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Immunogenicity of the tryptophan-rich motif (TrpM) in the membrane-proximal ectodomain of the transmembrane (TM) glycoprotein
of feline immunodeficiency virus (FIV) was investigated. Peptide 59, a peptide containing the TrpM of the TM of FIV, was covalently
coupled to Qh phage virus-like particles (Qh-59) in the attempt to induce potent anti-TrpM B cell responses in cats. All Qh-59 immunized
cats, but not cats that received a mixture of uncoupled Qh and peptide 59, developed antibodies that reacted with a same epitope in
extensive binding and binding competition assays. The epitope recognized was composed of three amino acids, two of which are adjacent.
However, Qh-59-immune sera failed to recognize whole FIV in all binding and neutralization assays performed. Furthermore, no reactivity
against the TrpM was detected by screening sera from FIV-infected cats that had reacted with TM peptides, confirming that this epitope
does not seem to be serologically functional in the FIV virion. The data suggest that TrpM may not be a suitable target for antiviral
vaccine design.
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The transmembrane (TM) glycoproteins of many fuso-
genic viruses possess a stretch unusually rich in tryptophans
(Trp) and other aromatic amino acids (Trp-rich motif;
TrpM) at their pretransmembrane domains, leading to
postulate that such a stretch plays a key part in the im-
portant functions these molecules exert in virus–cell sur-
face interactions (reviewed in Peisajovich and Shai, 2003).
Indeed, for the TM glycoproteins most intensively investi-
gated under this respect, human immunodeficiency type-1
(HIV-1) and vesicular stomatitis viruses, mutagenesis stud-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.02.017
* Corresponding author. Mailing address: Dipartimento di Patologia
Sperimentale, Universita` di Pisa, via San Zeno 37, I-56127 Pisa, Italy. Fax:
+39-050-2213639.
E-mail address: bendinelli@biomed.unipi.it (M. Bendinelli).
1 These authors contributed equally.ies have demonstrated that an intact TrpM is essential for
effective virus entry into cells (Jeetendra et al., 2003;
Mun˜oz-Barroso et al., 1999; Robison and Whitt, 2000;
Salzwedel et al., 1999). Moreover, in HIV-1, certain syn-
thetic peptides that inhibit entry and neutralizing monoclo-
nal antibodies 2F5 and 4E10 interact with the TM
glycoprotein at sites that partially or nearly entirely overlap
the TrpM (Chan and Kim, 1998; Zwick et al., 2001),
indicating that this site can be an interesting target for
antiviral strategies.
A similarly located TrpM is also present in the TM
glycoprotein of feline immunodeficiency virus (FIV), and
two lines of evidence have recently shown that it plays a
critical role in virus entry. First, short synthetic peptides
containing the region were found to be powerfully inhibi-
tory for FIV replication and to be dependent for their
activity on conservation of the Trp residues (Giannecchini
et al., 2003). Second, mutants carrying severe disruptions of
the TrpM adsorbed normally onto feline lymphoid cells but
G. Freer et al. / Virology 322 (2004) 360–369 361failed to enter, although mutants with minor changes in the
motif entered cells with reduced efficiency (Giannecchini et
al., 2004). It was therefore of interest to investigate whether
the TrpM might represent a suitable target for immunolog-
ical anti-FIV strategies.
In the present report, immunization of cats with an
appropriate FIV peptide conjugated to virus-like particles
(VLP) of the Qh phage, used to enhance B-cell reactivity
against the peptide (Lechner et al., 2002), led to the
generation of antibodies that specifically bound a confor-
mation-dependent epitope within the TrpM peptide in
enzyme-linked immunosorbent assays (ELISA). However,
the TrpM was found not to be serologically functional in
the context of the FIV virion, as shown by failure of the
immune sera thus raised to recognize the virus in binding
and neutralization assays and by failure of FIV-infected
cat sera to react with the motif in binding and binding
competition assays. These findings suggest that the TrpM
of FIV cannot be easily exploitable in devising antibody-
based antiviral strategies.Fig. 1. Peptides used. (A) Schematic representation of the TM glycoprotein of F
methionine of Env, according to the sequence of clone 34TF10 of FIV Petaluma
(Richardson et al., 1998): FC, fusion peptide; LZ, leucine zipper region; C–C, cy
spanning segment; Cyto, cytoplasmic region. (B) Amino acid sequence of the T
amino acids forming the TrpM are in bold. (C) Helical wheel projection of the
recognized by immunizing cats with Qh-59 are circled. (D) Schematic representa
antibodies.Results
Antibodies to selected TM-derived peptides in peptide
59-immunized cats
Wewanted to produce antibodies against the TrpM of FIV
(Fig. 1). However, peptide 59, used to this purpose in
previous studies, had failed to induce a humoral response
in mice (Massi et al., 1997). In order to enhance the
immunogenicity of peptide 59, we coupled it to VLP derived
from the bacteriophage Qh (Qh-59; Fig. 2). It has previously
been shown that antigens coupled to these VLP are highly
immunogenic (Fehr et al., 1998; Jegerlehner et al., 2002a;
Lechner et al., 2002; Pumpens et al., 1995). Specific-path-
ogen-free (SPF) cats were subsequently immunized with
Qh-59 (78 Ag of Qh-59 per cat carrying 2.5 Ag of peptide
59). To determine whether such an immunization had gen-
erated an antipeptide 59 antibody response, preimmune and
postimmune sera were diluted 1:100 and tested in ELISA
plates coated with peptide 59, as well as with peptides 58 andIV. Superscript figures denote amino acid positions starting with the first
(Talbott et al., 1989). TM domains are indicated as previously described
steine loop; gray box, membrane-proximal a-helix; solid box, membrane-
M in the tract used for modeling the synthetic peptides investigated. The
TrpM; the three amino acids essential for functionality of the B epitope
tion of the MAP-C8 used in serological assays for detection of anti-TrpM
Table 1
Summary of the reactivity exhibited by Qh-59-immunized and FIV-infected
cats against the synthetic peptides included in the study, as determined in
direct ELISA tests








59 0/4b 0/3 0/24
58 0/4 0/3 0/24
60 0/4 0/3 0/24
L361 4/4 0/3 14/24
E29K 0/4 0/3 14/24
L15P 0/4 0/3 0/24
C8 0/4 0/3 0/24
Map-C8 4/4 0/3 0/24
a Preimmune sera consistently negative against all peptides.
b Positive/tested.
Fig. 2. SDS-PAGE analysis of the efficiency of coupling peptide 59 to Qh.
Twenty micrograms of Qh (lane 1) or Qh-59 were analyzed on a 12% SDS-
PAGE gel under reducing conditions, and the relative intensity of coupled
Qh (solid arrow) and uncoupled (empty arrow), corresponding to a
molecular mass of 14 kDa, was compared after Coomassie Blue staining
and densitometric analysis. Lane 2: Molecular mass markers.
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respectively (Fig. 1). No evidence of antibody reactivity
could be detected in any of the test samples with any of the
three peptides (Table 1). We then ran similar assays using as
an antigen peptide L36I, that is, an adjacent and partially
overlapping 36-mer that contained a sequence of 11 amino
acids identical to the N-terminal portion of peptide 59 at its
C-terminal (Fig. 1). Use of this larger peptide led to the
demonstration of substantial antibody reactivity in all the
animals immunized with Qh-59 but in none of the preim-
mune sera or of the sera obtained from the animals injected
with a mixture of uncoupled peptide and VLP (Table 1). As
shown by Fig. 3, the antibodies detected by peptide L36I
became first evident at the time of the third inoculum and
reached the highest levels after the fourth dose. At this time,
they ranged in titer between 1:200 and 1:400 in individual
animals but subsequently declined rapidly and remained low
in spite of boosting (data not shown). Epitope density on
VLP surface has been shown to play a significant role in the
induction of a strong IgG response in mice, leading to
hypothesize that the higher the epitope density, the stronger
the stimulus for B cells (Jegerlehner et al., 2002b). It is likely,
therefore, that improving coupling efficiency between Qh
and peptide 59 might lead to higher and more durable
antipeptide antibody titers. Unfortunately, the physicochem-
ical features of the peptide chosen, especially its low solu-
bility in water, did not allow to improve coupling efficiency,
at least with the protocol used in the present study.
When similar ELISA tests were performed with the
29-mer E29K, no reactivity was detected in any of the test
sera. Because this peptide encompassed most of the se-
quence of peptide L36I but lacked the tract this shared with
peptide 59 (Fig. 1), this clearly suggested that, as expected,
the L36I-reactive antibodies in the Qh-59-immunized cats
were specific for the TrpM-containing segment.Antibodies to the TrpM in peptide 59-immunized cats
In these experiments, we looked for a confirmation that
the antipeptide L36I antibodies detected in Qh-59 immu-
nized cats were indeed directed against peptide 59 and, at
the same time, investigated whether they were specific for
the TrpM contained in the latter. This was done by exam-
ining whether short peptides that contained the TrpM alone
(peptide C8) or the TrpM flanked by few amino acids on
one side (peptide 58) or both sides (peptide L15P) could
directly bind antibody activity and compete with anti-L36I
peptide serum reactivity present in all Qh-59-immunized
cats. As controls, we used two peptides of comparable
length, one that reproduced a tract of the TM glycoprotein
just outside the TrpM (peptide 60; Fig. 1) and the other a
scrambled version of the TrpM (peptide C8scr). As summa-
rized in Table 1, all the direct binding assays conducted with
these peptides were consistently negative. On the other
hand, the competition experiments were extremely informa-
tive. Indeed, as illustrated by Fig. 4, which depicts the
results of a typical experiment, all the peptides encompass-
ing the TrpM (namely, peptides 58, 59, L15P, and C8)
completely blocked antibody binding to L36I although
control peptides 60 and C8scr did not, thus clearly indicating
that the L36I-reactive antibodies present in all 4 Qh-59
immunized cats were specific for the TrpM. This conclusion
was then substantiated by producing a four-branched tetra-
meric analogue of peptide C8 (MAP-C8; Fig. 1) and using it
to test the immune sera in ELISA. Indeed, all Qh-59
immune sera, but not control sera, reacted with MAP-C8
(Table 1).
Fine mapping of the TrpM B epitope recognized by peptide
59-immunized cats
The above results had shown that the sera of Qh-59-
immunized cats specifically reacted with a sequence repro-
ducing the TrpM of FIV TM. The reaction occurred with
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Fig. 3. TM L36I peptide antibody reactivity detected in sera from cats immunized with Qh-59 or a mixture of uncoupled Qh and peptide 59. Sera were
obtained from cats immunized with either Qh-59 (solid labels) or a mixture of uncoupled Qh and peptide 59 (empty labels) at the time of each immunization
(arrowheads) and 3 weeks after, diluted 1:100 and analyzed for L36I binding antibody on L36I-coated microwells by ELISA. Values, expressed as optical
density (OD), are the means of duplicates that did not differ by more than 10%.
G. Freer et al. / Virology 322 (2004) 360–369 363both large and short peptides, provided that the latter were in
solution (not plastic-bound). It was therefore of interest to
obtain a better definition of the precise epitope(s) involved.
We thus investigated how a series of analogues of peptide
C8, each having a different amino acid position substituted
with alanine, behaved in binding competition with peptide
L36I. As shown in Fig. 5, the analogues having an Ala
substituted for the Trp at position 770, the Trp at position
773, or the valine at position 774 exhibited a markedly
reduced ability to compete, essentially behaving as control
C8scr, whereas all others competed as effectively as the
unsubstituted peptide C8. Furthermore, the competition
profile was similar irrespective of the immune serum used,
showing that the epitope recognized did not vary in indi-
vidual animals.Fig. 4. Ability of selected peptides to compete with the anti-L36I peptide sera bin
(100 Al) were incubated 30 min at room temperature with the indicated competitor
binding to peptide L36I-coated ELISA microwells. Binding was calculated using
peptide/mean OD obtained with serum preincubated with diluent alone 100.Lack of seroreactivity of the TrpM in FIV virions and during
FIV infection
The above results had clearly indicated that the sequence
corresponding to the TrpM of FIV TM contained at least
one potential B epitope. It was therefore important to
ascertain whether the antipeptide 59 antibodies produced
by immunizing cats with Qh-59 bound FIV virions. No
evidence of such reactivity was detected in ELISA tests
using either intact or sonicated gradient-purified whole FIV
virions as antigens, as well as in immunoblots under
denaturing conditions (data not shown). Also, although
adsorption of FIV-infected cat sera with purified virus and
especially cell-adsorbed virus, but not with cells alone,
removed a measurable amount of reactivity to peptideding reactivity of individual Qh-59-immunized cat sera. Sera diluted 1:100
peptides (10 Ag/ml, final concentration) or diluent alone and then tested for
the formula: mean OD obtained with serum preincubated with competitor
Fig. 5. Alanine scanning analysis of the B epitope recognized by Qh-59-immunized cats. A series of analogues of peptide C8, each having a different amino
acid position substituted with an Ala, were analyzed for their ability to compete with the binding reactivity to peptide L36I-coated ELISA microwells exactly as
described in Fig. 4.
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from the Qh-59-immunized cat sera (Fig. 6). Finally, FIV
neutralizing activity in Qh-59 immune cat sera was also
undetectable by sensitive assays using either a recent virus
isolate (FIV-M2) or a tissue culture-adapted strain (FIV-Pet)
(data not shown).
In complementary experiments, we also examined
whether the TrpM could evoke a humoral immune response
during the course of FIV infection. This was done by testing
sera of SPF cats at various times of infection with two
strains of FIV against the entire set of peptides used in the
study by ELISA. Several such sera reacted with peptides
L36I and L29K, often at substantial levels, but none reacted
with any of the other peptides (Table 1). Importantly,
infected cat sera failed to react with any of the test peptides,Fig. 6. Ability of FIV virions, substrate cells, or virus–cell mixtures to remove p
infected cats. Pooled FIV-infected or Qh-59-immunized cat sera were diluted 1:100
105), and virions and cells (5 Ag of FIV proteins with 5 105 cells) or diluent alone
at 600  g for 15 min (to remove cells) followed by 20000  g for 90 min (to re
microwells.including MAP-C8, that were instead recognized by Qh-59-
immunized cat sera. This makes it highly unlikely that some
of the infected cat sera reactivity against peptide L36I was
directed to the TrpM. This was, however, further explored
by examining whether the binding of selected infected cat
sera to peptide L36I could be competed with the use of
peptides. As shown by Fig. 7, the only peptide other than
the homologous peptide that consistently proved capable of
competing in these assays was peptide E29K, that is, a
peptide that overlapped peptide L36I but lacked the TrpM.
The TrpM-containing peptides 59, L15P, and C8 were
instead completely ineffective, although peptide 58 showed
marginal competing ability, if any, possibly because of the
N-terminal overlap with peptide L36I. It was therefore
concluded that the antipeptide L36I reactivity observed ineptide L36I binding activity from the sera of Qh-59-immunized and FIV-
and preincubated with virions (5 Ag of FIV proteins), viable cells alone (5
at 4 jC for 1 h, followed by 1 h at 37 jC. Adsorbed cat sera were centrifuged
move virions) and tested for binding activity to peptide L36I-coated ELISA
Fig. 7. Ability of selected peptides to compete with anti-L36I antibody binding reactivity of FIV-infected cat sera. Ten FIV-Pet-infected and 4 FIV-M2-infected
cat sera that had shown anti-L36I reactivity in the experiment in Table 1 were diluted 1:100 (100 Al), incubated 30 min at room temperature with the indicated
peptides (10 Ag/ml, final concentration) or with diluent alone, and then tested for binding activity to peptide L36I-coated ELISA microwells. Results are
expressed as in Fig. 4.
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peptide other than the TrpM, and that the potential B epitope
that had been detected in the sequence corresponding to the
TrpM of FIV by immunizing cats with Qh-59 could not be
shown in the context of intact FIV virions.Discussion
In recent years, the C-terminal half of the ectodomain of
the HIV-1 TM glycoprotein has attracted considerable
attention as a structure onto which antiviral drugs that block
virus entry into cells can be modeled or targeted. Indeed,
one such HIV-1 fusion inhibitor (T20 or enfuvirtide) is
already in clinical use, and others are currently under active
development (Doms and Moore, 2000; Jiang et al., 2002;
Kilby et al., 1998; LaBranche et al., 2001). Moreover, at
least two broadly reactive HIV-1 neutralizing monoclonal
antibodies hitherto developed have been found to recognize
amino acid sequences belonging to such a domain, and this
has stimulated studies on the possibility of developing
immunoprophylactic and immunotherapeutic agents targeted
to the same region (Marusic et al., 2001; McGaughey et al.,
2003; Muster et al., 1993; Parker et al., 2001; Xiao et al.,
2001; Zwick et al., 2001).
FIV shares numerous biological and pathogenetic prop-
erties with HIV and is therefore an advantageous small
animal model for exploring the feasibility of novel thera-
peutic and vaccinal strategies (Pedersen et al., 1987;
reviewed in Elder et al., 1998; Overbaugh et al., 2001;
Willett et al., 1997). In particular, the envelope glycopro-
teins of FIV and HIVexhibit common structural frameworks
and seem to play similar roles in cell entry (de Parseval andElder, 2001; Wyatt and Sodroski, 1998). In the present
study, we analyzed the serological properties of the TrpM
located in the C-terminal part of the ectodomain of the TM
glycoprotein of FIV, in proximity of the transmembrane
segment of the molecule. In analogy to what was observed
for the corresponding zone of HIV-1 (Mun˜oz-Barroso et al.,
1999; Salzwedel et al., 1999), it has been shown that the Trp
residues present in the TrpM of FIV need to be conserved
for efficient virus entry into cells (Giannecchini et al.,
2004). Furthermore, this tract of the TM of FIV has been
successfully used to model powerful inhibitory peptides,
one of which (peptide C8) is only eight amino acids long
and hence contains the TrpM alone (Giannecchini et al.,
2003). It was therefore logical to investigate whether the
TrpM of FIV might also represent a suitable target for
immune intervention.
We started by ascertaining whether in the FIV TrpM
contains potential epitopes capable of evoking an antibody
response in cats. This was achieved by immunizing with the
TrpM-containing peptide 59 covalently linked to recombi-
nant Qh VLP. Such a 20-mer peptide appeared particularly
suitable because (i) its small size limited the number of
possible non-TrpM epitopes; (ii) it had previously been
shown to inhibit FIV replication in vitro (Lombardi et al.,
1996), thus indicating that its TrpM, that is, the segment of
the peptide responsible for such activity (Giannecchini et al.,
2003), was in a biologically active conformation; and (iii)
the presence in it of short amino acid tails at both sides of
the TrpM was likely to permit its coupling without much
distortion of the motif. Coupling the peptide to VLP was
considered necessary because, in previous studies, un-
coupled peptide 59 had failed to generate antibodies when
administered to mice in Freund’s complete adjuvant (Massi
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repetitive and organized arrays, and this has been shown to
turn them into strong B cell activation stimuli (Jegerlehner et
al., 2002a). Indeed, VLP have been successfully used to
achieve potent B cell responses with poorly immunogenic
peptides in the absence of adjuvants (Fehr et al., 1998;
Jegerlehner et al., 2002b; Pumpens et al., 1995). The
advantages of using Qh VLP to this purpose have been
recently illustrated (Jegerlehner et al., 2002a).
The immunization procedure that was chosen proved
effective because all four cats given Qh-59, but none of
those who received a mixture of uncoupled Qh VLP and
peptide 59, developed antipeptide antibodies, which proved
specific for the TrpM in extensive binding and binding
competition assays. Notably, TrpM-specific antibodies were
revealed by a 36-mer TrpM-containing peptide in binding
assays, but not by four much shorter (8- to 20-mer) peptides
that also contained the TrpM. However, all of the latter,
including peptide C8 that consisted of the TrpM alone, were
effective in inhibiting the binding of peptide 59-specific
antibodies to the 36-mer peptide, thus showing that the
epitope(s) involved belonged to the TrpM sequence. Al-
though alternative explanations remain possible, it is likely
that short peptides lost reactivity after having adhered to
plastic because the epitope recognized was conformation-
dependent (Joyce et al., 2002). Indeed, all positive sera
reacted against MAP-C8, most likely because at least one
peptide chain in this tetrameric analogue of peptide C8
remained available for antibody–antigen reaction (Caponi
et al., 1995). In keeping with this possibility, alanine
scanning of peptide C8 showed that the sera of all four
Qh-59 immunized cats reacted with a same epitope and that
this was composed of three amino acids, two of which are
nonadjacent. Interestingly, two of these were Trp, that is,
residues previously shown to play a key role in the func-
tion(s) the TrpM exerts in cell entry (Giannecchini et al.,
2004). In addition, the Trp residues have been found to
determine the a-helix conformation the inhibitory peptide
C8 has when it is dissolved in physicochemical conditions
compatible with biological environments (Giannecchini et
al., 2003). It is also noteworthy that the three amino acids
that make up the epitope are closely associated and lye on
the hydrophobic face of the helical wheel projection of the
TrpM (Fig. 1). In the solid-phase context of direct ELISA,
particularly in short peptides, this face is likely to interact
directly with the plastic support, thus becoming unavailable
for antibody binding.
Anti-TrpM sera, together with the panel of TM-derived
peptides used for their characterization, were then exploited
to investigate whether the TrpM is serologically active in the
context of whole FIV virions and in the course of FIV
infection. None of several methods used demonstrated
binding of the anti-TrpM antisera to intact, sonicated, or
cell-adsorbed FIV virions. Furthermore, the antisera failed
to block infectivity of FIV in sensitive neutralization tests,
no matter whether the virus used was of recent isolation ortissue culture-adapted. To sum up, all of the approaches
used pointed to the conclusion that the TrpM is not available
to antibodies on FIV virions, not even when these are
interacting or have interacted with the cell surface. At least
in HIV-1, such interaction has been shown to uncover novel
epitopes not expressed by unadsorbed virions and to bring
about conformational changes of the glycoprotein complex
that ultimately lead to cell entry (Doms and Moore, 2000;
Golding et al., 2002). In addition, we found no evidence that
anti-TrpM antibodies are produced in the course of FIV
infection of cats. In fact, none of the sera taken from
numerous FIV-infected cats exhibited antibodies that bound
the TrpM or competed with the anti-TrpM sera elicited with
Qh-59 in binding to such a motif. Although previous studies
have used synthetic peptides to dissect the humoral response
of FIV-infected cats (Avrameas et al., 1993; de Ronde et al.,
1993; Pancino et al., 1993; Richardson et al., 1998), whether
the TrpM is immunogenic in the course of FIV infection has
not yet been specifically addressed. In one such study,
peptides containing different segments of the TrpM, as well
as short upstream and downstream sequences, were found to
react with variable proportions of infected cat sera, but no
attempts were made to exactly identify the epitopes in-
volved (Avrameas et al., 1993). In HIV-1, TrpM-containing
peptides of various lengths have been shown to react with
highly variable proportions of infected human sera; howev-
er, the consensus is that the TrpM is poorly immunogenic, if
at all. This is in line with the failure to elicit HIV-1 immune
responses in recent attempts using immunogens modeling
this, nearby or adjacent regions (Calarota et al., 1996;
Conley et al., 1994; Muster et al., 1993; Xiao et al., 2001;
Zwick et al., 2001).
According to current models, the TrpM of HIV-1 is
highly flexible and it undergoes sequential conformation
transitions from a closed turn to an extended arrangement
and finally to an amphipathic a-helical structure as a result
of TM activation following virus interaction with suscepti-
ble cells. The latter conformation would then be suitable for
intimate and concomitant interaction with the viral and the
cell membrane (Barbato et al., 2003), thus allowing Trp
residues, with their bulky indole side chains, to destabilize
both membranes and drive their fusion alone or in synergy
with the fusion peptide (Melikyan et al., 2000; Peisajovich
and Shai, 2003; Schibli et al., 2001; Sua´rez et al., 2000). It
seems therefore possible that the conformation-dependent B
epitope we have demonstrated in the TrpM of FIV by
immunizing cats with Qh-59 is available only when the
TrpM has an a-helical conformation. This is when the viral
and the cell membrane are too close to each other to be
accessible to antibodies (Finnegan et al., 2001; Giannec-
chini et al., 2002), thus explaining why we were unable to
demonstrate such an epitope on virions, no matter whether
free or cell-associated. On the other hand, the flexible nature
of the TrpM might render it a poor immunogen during FIV
infection, thus explaining why it was found to be completely
serologically silent in infected cats. In any case, there would
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easy target for antibody-based antiviral strategies. It should,
however, be noted that the implications of these findings
cannot be directly extrapolated to HIV-1 without further
investigation, because the TrpM of this virus differs from
the TrpM of FIV under several regards, including number
and spacing of Trp residues, that might bring about differ-
ences in their immunological behavior.Materials and methods
Animals, cells, and viruses
SPF female cats were purchased from Iffa Credo (L’Ar-
bresle, France) and immunized when 7–12 months old.
Animals were housed in our climatized animal facility under
conditions required by the European Community Law. The
viruses used were FIV-Pet and FIV-M2. The former was a
tissue culture-adapted strain of clade A and was obtained
from chronically infected FL4 cells (kindly provided by Dr.
J. Yamamoto, Gainesville, FL), while the latter was a
recent isolate of clade B and was grown in MBM cells.
MBM cells are an interleukin (IL)-2-dependent line of T
lymphocytes originally established from the peripheral
blood mononuclear cells of an FIV- and feline leukemia
virus-negative cat (Matteucci et al., 1995). They are rou-
tinely grown in RPMI 1640 medium supplemented with
10% fetal bovine serum, 5 Ag of concanavalin A and 20 U
of IL-2 per ml.
Peptide synthesis
Synthetic peptides (Fig. 1) were prepared manually by a
conventional solid-phase strategy, as described previously
(D’Ursi et al., 2003). Crude peptides were purified by semi-
preparative reverse-phase high-pressure liquid chromatogra-
phy (HPLC) to a purity greater than 95% and lyophilized.
Final products were characterized by analytical HPLC and
electrospray mass spectrometry (ESI-MS). MAP-C8 was
synthesized starting from a branched poly-lysine central
core, prepared coupling on the resin two levels of Fmoc-
Lys(Fmoc)-OH onto a h-alanine residue, as shown in Fig. 1.
The crude peptide was lyophilized twice, characterized by
ESI-MS, and used without further purification.
Expression and purification of Qb
Capsids of phage Qh were expressed using the expres-
sion vector pQh10 and purified as described (Cielens et al.,
2000; Kozlovska et al., 1993). In brief, E. coli lysates
containing the expressed coat protein were cleared by
centrifugation. Proteins from the supernatant were fraction-
ated by ammonium sulfate precipitation (at final concen-
trations of 20% and 40% saturation, sequentially). The
precipitated capsids were resuspended in a minimal volumeof gel filtration buffer containing 20 mM Tris–HCl, pH 7.8,
5 mM EDTA, and 150 mM NaCl and purified over a
Sepharose CL-4B column (Amersham Bioscience, Uppsala,
Sweden). Eluted capsids were precipitated with polyethyl-
ene glycol-6000 at 13.3% saturation and repurified on a
Sepharose CL-4B column. Capsids present in the peak
fractions were precipitated with ammonium sulfate at 60%
saturation. Sedimented VLP were resuspended in gel filtra-
tion buffer and loaded onto a Sepharose CL-6B column
(Amersham Bioscience). Fractions containing the Qh were
pooled, concentrated by ammonium sulfate precipitation,
and dialyzed against 20 mM HEPES, 150 mM NaCl, pH 7.4.
Coupling of peptide 59 to Qb
Qh VLP (2 mg/ml) were mixed with a fivefold molar
excess of the cross-linker succinimidyl-6-[h-maleimido-
propionamido]hexanoate (Pierce, Rockford, USA) and
incubated for 30 min at room temperature. The reaction
was performed in 20 mM HEPES, 150 mM NaCl, pH 7.2.
Free, unreacted cross-linker was removed by dialysis against
50 mM phosphate, 150 mM NaCl, pH 6.5 (coupling buffer),
using SnakeSkinR dialysis membranes (Pierce) with a cutoff
of 3.5 kDa. Derivatized Qh VLP was mixed with a half
molar equivalent (based on the concentration of the subunits)
of peptide 59 containing a C-terminal cysteine, dissolved in
dimethyl sulfoxide (DMSO), and incubated at 15 jC for 2
h to obtain Qh-59. Uncoupled peptide was removed by
dialysis with Slide-A-LyzerR Cassettes, cutoff 10 kDa
(Pierce), against coupling buffer overnight at 4 jC. Coupling
efficiency was evaluated by SDS-PAGE analysis and density
measurement of the uncoupled Qh band versus the heavier
peptide-coupled one (Fig. 2).
Because of its high content in hydrophobic residues,
peptide 59 tended to precipitate out of aqueous solution. For
this reason, DMSO was used to dissolve the peptide, and it
was present in the buffer during coupling at a maximal
concentration of 10%. Nevertheless, peptide 59 could be
found also as a precipitate at the end of the coupling reaction
(not shown). This was probably the reason why, in repeated
attempts, coupling efficiency between Qh subunits and
peptide 59, expressed as ratio between the densities of the
coupled and uncoupled Qh bands, was never higher than
20%. For the present study, we used antigen derived from a
same coupling reaction, in which the proportion of coupled
VLP subunits was approximately 17% (Fig. 2). Although
suboptimal, this extent of coupling was considered suffi-
cient for a proof-of-concept study.
Immunization schedule
Four SPF cats were inoculated subcutaneously with 78 Ag
of coupled Qh-59 carrying total 2.5 Ag of peptide 59, while
three controls were inoculated with a mixture of 78 Ag of Qh
and 2.5 Ag of uncoupled peptide. Four doses were adminis-
tered at 2.5-week intervals, and serum was obtained from
G. Freer et al. / Virology 322 (2004) 360–369368each cat before the first inoculum, at the time of every
immunizing dose, and 3 weeks after the last inoculum. All
procedures were carried out under light anesthesia.
Antibody binding, binding competition, and neutralization
assays
Total cat immunoglobulin G (IgG) to gradient-purified
and sonicated whole FIV and TM peptides were measured
by ELISA, as previously described (Mazzetti et al., 1999).
Briefly, ELISA microwells were coated overnight with 100
Al of 1 Ag/ml of either whole FIV or 10 Ag/ml of the
synthetic peptides in carbonate buffer, pH 9.6. After a
postcoating step with skim milk, serially diluted sera were
added to the plates in duplicate. Bound IgG was revealed
with a mouse anti-cat IgG antibody followed by a goat anti-
mouse peroxidase conjugate. Virus neutralization tests were
performed against 10 TCID50 of FIV by using MBM cells as
indicator cells and quantitation of reverse transcriptase
activity in the supernatant as an end point read-out, exactly
as described (Giannecchini et al., 2002).Acknowledgments
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